Browse by People

Collapse authors list.
Munir, Talha, Cairns, David A, Bloor, Adrian, Allsup, David, Cwynarski, Kate, Pettitt, Andrew, Paneesha, Shankara, Fox, Christopher P, Eyre, Toby A, Forconi, Francesco et al (show 23 more authors) , Elmusharaf, Nagah, Kennedy, Ben, Gribben, John, Pemberton, Nicholas, Sheehy, Oonagh, Preston, Gavin, Schuh, Anna, Walewska, Renata, Duley, Lelia ORCID: 0000-0001-6721-5178, Howard, Dena, Hockaday, Anna, Jackson, Sharon, Greatorex, Natasha, Girvan, Sean, Bell, Sue, Brown, Julia M, Webster, Nichola, Dalal, Surita, de Tute, Ruth, Rawstron, Andrew, Patten, Piers EM, Hillmen, Peter and National Cancer Research Institute Chronic Lymphocytic Leukemia, (2023) Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease. The New England journal of medicine.

Collapse authors list.
Schuh, Anna H, Parry-Jones, Nilima, Appleby, Niamh, Bloor, Adrian, Dearden, Claire E, Fegan, Christopher, Follows, George, Fox, Christopher P, Iyengar, Sunil, Kennedy, Ben et al (show 7 more authors) , McCarthy, Helen, Parry, Helen M, Patten, Piers, Pettitt, Andrew R, Ringshausen, Ingo, Walewska, Renata and Hillmen, Peter (2018) Guideline for the treatment of chronic lymphocytic leukaemia: A British Society for Haematology Guideline. BRITISH JOURNAL OF HAEMATOLOGY, 182 (3). pp. 344-359.

Collapse authors list.
Pettitt, Andrew R, Jackson, Richard, Cicconi, Silvia ORCID: 0000-0001-5507-6203, Polydoros, Fotis, Yap, Christina, Dodd, James, Bickerstaff, Matthew, Stackpoole, Michael, Khan, Umair T ORCID: 0000-0002-9470-3481, Carruthers, Stacey et al (show 16 more authors) , Oates, Melanie, Lin, Ke, Coupland, Sarah E ORCID: 0000-0002-1464-2069, Menon, Geetha, Kalakonda, Nagesh ORCID: 0000-0002-5300-1360, McCarthy, Helen, Bloor, Adrian, Schuh, Anna, Duncombe, Andrew, Dearden, Claire, Fegan, Christopher, Kennedy, Ben, Walewska, Renata, Marshall, Scott, Fox, Christopher P and Hillmen, Peter (2020) Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukemia: final results of the NCRI CLL210 trial. HAEMATOLOGICA, 105 (12). pp. 2868-2871.